

## ISRAELI PATENT ISSUED IN BARD1 CORE PATENT FAMILY

- **Israeli Patent No 224766 issued**
- **Patent family provides protection for BARD1-Lung test**

**Perth, Australia, 21 March 2018:** BARD1 Life Sciences Limited (ASX:BD1), a biotechnology company developing non-invasive cancer diagnostics, today announced that on 1<sup>st</sup> March 2018, the Israeli Patent Office issued Israeli Patent number 224766 titled “BARD1 isoforms in lung and colorectal cancer and use thereof”.

This patent family protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, methods for detecting the presence of the specific BARD1 isoforms, and methods for treating and/or preventing lung cancer and colorectal cancer. The patent was filed in the name of Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17<sup>th</sup> August 2011 and expires on 17<sup>th</sup> August 2031. BARD1 LSL (via its fully owned subsidiary BARD1AG SA) has licensed the commercial rights to exploit this technology from UNIGE and HUG.

BARD1 LSL CEO, Dr Leeorne Hinch commented: “This core patent family now has 6 granted patents in the US, Japan and Japan divisional, Israel, China and Australia, with other jurisdictions pending. The BARD1 LSL patent portfolio includes 5 patent families covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers.”

The BARD1-Lung test is in development for the early detection of lung cancer. Lung cancer is the fifth most common cancer and the leading cause of cancer death in Australia. The Australian Institute of Health and Welfare (AIHW) estimates that there will be 12,741 new cases of lung cancer diagnosed (9.2% of all new cancers diagnosed) and 9,198 deaths from lung cancer (18.9% of all cancer deaths) in Australia in 2018<sup>1</sup>. Lung cancer is often diagnosed at a later stage after it has spread to other parts of the body, resulting in a 15.8% chance of survival after 5-years in Australia. Early detection of lung cancer has the potential to save people’s lives by enabling earlier treatment when it is potentially curable. There is currently no approved blood test available for screening of lung cancer in people without symptoms.

- ENDS -

### FOR MORE INFORMATION PLEASE CONTACT:

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

**Dr Leeorne Hinch**  
CEO  
E [leeorne@bard1.com](mailto:leeorne@bard1.com)  
M +61 400 414 416

### ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The development pipeline includes two BARD1 autoantibody tests in early development for early detection of lung and ovarian cancers, and a cancer vaccine project at research-stage for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

<sup>1</sup> AIHW 2017. Cancer in Australia 2017. Available <https://www.aihw.gov.au/getmedia/521126f1-fe5f-47a0-a810-832e301a65ff/summary-pages-for-selected-cancers-cancer-2017.pdf.aspx>, accessed Feb 1, 2018.

## ABOUT THE BARD1 INTELLECTUAL PROPERTY PORTFOLIO

BARD1 has established a strong intellectual property position covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers. The patent portfolio comprises 5 patent families with multiple granted and pending patents across key marketplaces including the US, Europe and Japan. In addition, the algorithms are protected by trade secret.

Figure 1: BARD1 Patent Status

Patent Family	Title	Granted	Pending	Expiry
PCT/FR01/02731	Truncated BARD1 protein and its diagnostic and therapeutic uses	US, JP		2023*
PCT/IB2011/053635	BARD1 isoforms in lung and colorectal cancer and use thereof	US, JP, JP div, IL, CN, AU	US, CN (divisionals), EP, CA, BR, SG, HK	2031*
PCT/IB2011/054194	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof		US, EP	2032*
PCT/EP2014/073834	Lung Cancer Diagnosis		US, EP, CA, JP, IL, CN, AU, SG, KR, HK	2034*
EP14002398.7	Novel non-coding RNA, cancer target and compounds for cancer treatment		US	2035*

\* Plus any extension of term in the US due to prosecution delay